Open AccessSurvivin and pancreatic cancer
Author(s) -
Binbin Liu,
Weihong Wang
Publication year - 2011
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v2.i3.164
Subject(s) - survivin , pancreatic cancer , medicine , adenocarcinoma , cancer , cancer research , pancreatic ductal adenocarcinoma , apoptosis , oncology , inhibitor of apoptosis , ca19 9 , pancreatic carcinoma , programmed cell death , biology , biochemistry
Pancreatic cancer is estimated to be the fourth most common cancer in men and fifth in women in the world and has poor prognosis. In recent years, more and more effort has been put on the relationship between pancreatic cancer and apoptosis. As a newly discovered inhibitor of apoptosis, survivin has drawn more attention. Strong evidence has shown that survivin is expressed in pancreatic cancer cells on frozen sections. Survivin increases in the development of pancreatic ductal adenocarcinoma and its expression can be a marker in evaluating the prognosis of pancreatic cancer patients. Survivin itself may be a new target in the treatment of pancreatic cancer and a survivin DNA vaccine could generate specific antitumor effects in pancreatic carcinoma models.